Nifedipine ER Formulation Considerations

Clinical Recommendations and Pharmacokinetic Differences

• The American College of Cardiology warns that immediate-release nifedipine must be avoided without concomitant beta-blockade due to increased adverse cardiovascular events, highlighting the importance of formulation considerations in nifedipine treatment 1, 2, 4
• Pharmacokinetic differences between ER formulations, including a 20-25% difference in drug exposure, can impact blood pressure control in patients and should be considered when switching during treatment 4, 5

Bioavailability and Food Effects

• No cited facts are available for this section

Sympathetic Nervous System Response

• No cited facts are available for this section